Jiangsu Jindike Biotechnology Co., Ltd. Report issue

Government Phase 4

Organization Overview

First Clinical Trial
2015
NCT02269007
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Jiangsu Jindike Biotechnology Co., Ltd.

Active Ingredients

Drugs in Phase 4 Trials (1)

inactivated influenza vaccine (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Influenza, Human (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 1